Most of us think that the legacy of Dr Harold Shipman -the serial-killing GP from Hyde in Greater Manchester (UK) -was to put another doctor in the murderers' record books above Bodkin-Evans and somewhat below Hitler, Stalin and Pol Pot. However he may leave a more important and pervasive legacy.
Dame Janet Smith conducted the official inquiry into the Shipman case, and after several years of evidence-taking, has published a series of volumes on all aspects of the case. In these, she has made many hundreds of recommendations relating to medical practice at all levels, from the regulation of controlled drugs to the role and mechanisms of the General Medical Council (GMC). Most of these recommendations have been accepted in principle by the Department of Health and are now out for consultation. They include the plan that all patients who are prescribed a controlled drug (i.e. much of the population over their lifetime) will have a unique identity number that will allow computer tracking of their prescriptions. This is designed to allow 'smart' IT technology to determine if a GP or other doctor is 'overprescribing' for an individual in a presumed attempt to kill them or to collect their drugs to kill others. In other words, the government is planning the introduction of individualised electronic records of drug prescriptions with the expressed purpose of e-surveillance of drug use -in effect a form of national electronic monitoring system.
This system will initially be introduced for prescriptions of class A opiate drugs so will first apply to patients in palliative or terminal care and those with opiate drug addiction. In the latter case the aim is e-surveillance of patients' activities -to prevent addicts collecting extra scripts from other doctors, or attempting to forge them. What it will allow is sophisticated computerised tracking of drug addicts' locations and individual drug prescriptions, so restoring the old 'addicts' index'. While this could be a real boon to epidemiologists interested in drug use and treatment compliance, the 'Big Brother' elements of this centralised database are worrying if access should fall into the hands of those whose interests are not simply healthcare provision.
It is interesting that the introduction of the first nation-wide form of e-surveillance will be in medicine. Perhaps less surprising is that it will be targeted at two of the most disadvantaged groups of society -those with addiction and those with enduring or terminal pain disorders. That it will reduce drug misuse by either doctors or addicts is an unproven assumption and, even if it does, there is still the ethical question of proportionality of gain versus the intrusion on personal freedom. Some may feel that this approach is inevitable given the planned introduction of computerised medical records, which will allow the same sort of e-monitoring. But the e-record is being introduced for the purpose of more efficient and informed treatment of patients, whereas the current proposals about controlled drugs are explicitly for the purpose of surveillance. Hopefully those of you with opinions on this subject will read the relevant documents and provide appropriate feedback to the authorities. Perhaps the BAP would like to offer an opinion?
